Jump to content

1F-LSD

From Wikipedia, the free encyclopedia
1F-LSD
Clinical data
Other names1-Formyl-LSD; 1-Formyl-N,N-diethyllysergamide; N,N-Diethyl-1-formyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
Routes of
administration
Oral; Sublingual
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • N,N-Diethyl-1-formyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
Chemical and physical data
FormulaC21H25N3O2
Molar mass351.450 g·mol−1
3D model (JSmol)
  • CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C=O)CC
  • InChI=1S/C21H25N3O2/c1-4-23(5-2)21(26)15-9-17-16-7-6-8-18-20(16)14(12-24(18)13-25)10-19(17)22(3)11-15/h6-9,12-13,15,19H,4-5,10-11H2,1-3H3/t15-,19-/m1/s1
  • Key:SSEPNHFOVYUBHO-DNVCBOLYSA-N

1F-LSD, or 1-formyl-LSD, also known as 1-formyl-N,N-diethyllysergamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is the 1-formyl derivative of LSD.[1][2][3]

The drug is assumed to act as a prodrug of LSD.[1] It produces psychedelic effects in humans similarly to LSD.[2] Effective doses have been reported to be 100 to 150 μg orally or sublingually.[2] Very little is known about the pharmacology and properties of 1F-LSD.[1]

1F-LSD was first described in the scientific literature by 2021.[2] It first emerged as a novel designer drug online in January 2019.[1][2]

Another compound, 1‐(furan‐2‐carbonyl)‐LSD (SYN-L-005), has also been referred to as "1F-LSD".[3]

See also

[edit]

References

[edit]
  1. ^ a b c d e "1F-LSD". АИПСИН (in Russian). Retrieved 26 July 2025.
  2. ^ a b c d e f Catalani, Valeria; Arillotta, Davide; Corkery, John Martin; Guirguis, Amira; Vento, Alessandro; Schifano, Fabrizio (9 February 2021). "Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach". Frontiers in Psychiatry. 11. doi:10.3389/fpsyt.2020.632405. ISSN 1664-0640.
  3. ^ a b Brandt, Simon D.; Kavanagh, Pierce V.; Gare, Sarah; Elliott, Simon P.; Stratford, Alexander; Halberstadt, Adam L. (3 December 2024). "Analytical and Pharmacological Characterization of 1‐(Furan‐2‐Carbonyl)‐LSD (1F‐LSD) and Comparison With 1‐(Thiophene‐2‐Carbonyl)‐LSD (1T‐LSD)". Drug Testing and Analysis. doi:10.1002/dta.3829. ISSN 1942-7603.
[edit]